BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty ...

Building on our progress this past year, Liquidia has strengthened its financial position, with up to an additional $100 million available pursuant to an amendment to its existing financing agreement ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

And that's not all. We're tremendously excited for the potential of Ralinepag to be the first true once-a-day oral prostacyclin agonist for pulmonary arterial hypertension patients. If successful ...

Right heart failure occurs when the heart is too weak to pump adequate blood supply to the lungs. Prostacyclin analogs were the first class of drugs approved for treating PAH. They work by mimicking ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

Triple therapy for PAH pulmonary vasodilator treatment target 3 potent mediators of vascular tone: nitric oxide, prostacyclin and endotelin pathway. The prostacyclin metabolic pathway is dysregulated ...